$NTRA

Rabinowitz Matthew sold $642K of NTRA (indirect holdings)

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $320.90 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Aug 8, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 1:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling optics, but the 10b5-1 structure makes it unlikely to drive a fundamental repricing by itself.

03

What to watch

The transaction is indirect and under a 10b5-1 plan; without additional context (e.g., total planned volume, prior sales), the signal is weak.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-07 after-hours; sale dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 2,000 shares in an open-market transaction at $320.90 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Likely minimal immediate impact; any effect is more about optics than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

A large insider sale can still coincide with private information, even if executed under a 10b5-1 plan, so traders may watch for follow-on disclosures.

Key entities

  • Natera, Inc.

    Company whose executive chairman insider sale is disclosed on Form 4.

  • Matthew Rabinowitz

    Executive chairman who sold 2,000 shares indirectly under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.